Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04800315 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 221
- Enrollment target
NCT04800315 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 221 participants.
The verdict
NCT04800315, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 221 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness and safety of 3 dose regimen of CC-93538 in adult participants with moderate to severe Atopic Dermatitis (AD).
Interventions
- OTHER Placebo
- DRUG CC-93538
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2021-05-14 |
| Est. Completion | 2022-11-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04800315
The ClinicalTrials.gov registry entry for NCT04800315 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04800315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04800315 about?
NCT04800315 is a clinical study titled "A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis". The purpose of this study is to evaluate the effectiveness and safety of 3 dose regimen of CC-93538 in adult participants with moderate to severe Atopic Dermatitis (AD).
What is the current status of trial NCT04800315?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 221 participants. The study started on 2021-05-14. Estimated completion is 2022-11-09.
What interventions are being tested in trial NCT04800315?
The interventions under investigation include: Placebo (OTHER), CC-93538 (DRUG).
Who is sponsoring clinical trial NCT04800315?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.